Downregulation of TM7SF4 inhibits cell proliferation and metastasis of A549 cells through regulating the PI3K/AKT/mTOR signaling pathway

Yang,Xudong; Song,Xiaoming; Wang,Xiaohang; Liu,Xiangyan; Peng,Zhongmin

doi:10.3892/mmr.2017.7324

Downregulation of TM7SF4 inhibits cell proliferation and metastasis of A549 cells through regulating the PI3K/AKT/mTOR signaling pathway

Authors:
- Xudong Yang
- Xiaoming Song
- Xiaohang Wang
- Xiangyan Liu
- Zhongmin Peng
View Affiliations

Affiliations: Department of Thoracic Surgery, Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China, Department of Thoracic Surgery, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: August 22, 2017 https://doi.org/10.3892/mmr.2017.7324
Pages: 6122-6127

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is one of the most common types of malignant tumor worldwide. The etiology of lung cancer is complex and, although significant progress has been made in previous investigations, the molecular mechanism responsible for lung cancer remains to be fully elucidated. In the present study, the association between lung cancer and transmembrane 7 superfamily member 4 (TM7SF4) was investigated. Reverse transcription‑quantitative polymerase chain reaction technology was used to detect the expression of TM7SF4, and it was expressed at a high level in lung cancer. Furthermore, by overexpressing and inhibiting the expression of TM7SF4, the present study compared cell proliferation and migration rates. It was confirmed that TM7SF4 promoted lung cancer cell proliferation and migration. TM7SF4 was also confirmed to promote cancer cell migration and invasion by modulating the activation of the phosphatidylinositol 3‑kinase/Akt pathway in the A549 cells. Correspondingly, the inhibition of TM7SF4 decreased the expression of proteins associated with AKT, whereas the overexpression of TM7SF4 promoted the expression of the relevant proteins. Therefore, the present study confirmed that TM7SF4 was involved in the progression of lung cancer via regulating the activation of AKT. These findings suggested that TM7SF4 may be involved in the progression of lung cancer and may be a novel therapeutic target for this disease.

View Figures

View References

1	D'Addario G, Früh M, Reck M, Baumann P, Klepetko W and Felip E; ESMO Guidelines Working Group, . Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21 Suppl 5:v116–v119. 2010. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403. 2013. View Article : Google Scholar : PubMed/NCBI
3	Sherwood JL, Corcoran C, Brown H, Sharpe AD, Musilova M and Kohlmann A: Optimised pre-analytical methods improve KRAS mutation detection in circulating tumour DNA (ctDNA) from patients with non-small cell lung cancer (NSCLC). PLoS One. 11:e01501972016. View Article : Google Scholar : PubMed/NCBI
4	Quéré G, Descourt R, Robinet G, Autret S, Raguenes O, Fercot B, Alemany P, Uguen A, Férec C, Quintin-Roué I and Le Gac G: Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer. BMC Cancer. 16:2102016. View Article : Google Scholar : PubMed/NCBI
5	Zequn N, Xuemei Z, Wei L, Zongjuan M, Yujie Z, Yanli H, Yuping Z, Xia M, Wei W, Wenjing D, et al: The role and potential mechanisms of LncRNA-TATDN1 on metastasis and invasion of non-small cell lung cancer. Oncotarget. 7:18219–18228. 2016. View Article : Google Scholar : PubMed/NCBI
6	Donáth J, Speer G, Kósa JP, Árvai K, Balla B, Juhász P, Lakatos P and Poór G: Polymorphisms of CSF1 and TM7SF4 genes in a case of mild juvenile Paget's disease found using next-generation sequencing. Croat Med J. 56:145–151. 2015. View Article : Google Scholar : PubMed/NCBI
7	Chung PY, Beyens G, de Freitas F, Boonen S, Geusens P, Vanhoenacker F, Verbruggen L, Van Offel J, Goemaere S, Zmierczak HG, et al: Indications for a genetic association of a VCP polymorphism with the pathogenesis of sporadic Paget's disease of bone, but not for TNFSF11 (RANKL) and IL-6 polymorphisms. Mol Genet Metab. 103:287–292. 2011. View Article : Google Scholar : PubMed/NCBI
8	Valerio MS, Herbert BA, Griffin AC III, Wan Z, Hill EG and Kirkwood KL: MKP-1 signaling events are required for early osteoclastogenesis in lineage defined progenitor populations by disrupting RANKL-induced NFATc1 nuclear translocation. Bone. 60:16–25. 2014. View Article : Google Scholar : PubMed/NCBI
9	Safdari Y, Khalili M, Ebrahimzadeh MA, Yazdani Y and Farajnia S: Natural inhibitors of PI3K/AKT signaling in breast cancer: Emphasis on newly-discovered molecular mechanisms of action. Pharmacol Res. 93:1–10. 2015. View Article : Google Scholar : PubMed/NCBI
10	Ye Y, Tang X, Sun Z and Chen S: Upregulated WDR26 serves as a scaffold to coordinate PI3K/AKT pathway-driven breast cancer cell growth, migration, and invasion. Oncotarget. 7:17854–17869. 2016. View Article : Google Scholar : PubMed/NCBI
11	McAuliffe PF, Meric-Bernstam F, Mills GB and Gonzalez-Angulo AM: Deciphering the Role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer. 10 Suppl 3:S59–S65. 2010. View Article : Google Scholar : PubMed/NCBI
12	Fu J, Lv H, Guan H, Ma X, Ji M, He N, Shi B and Hou P: Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway. BMC Cancer. 13:4622013. View Article : Google Scholar : PubMed/NCBI
13	Fumarola C, Bonelli MA, Petronini PG and Alfieri RR: Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochemical Pharmacol. 90:197–207. 2014. View Article : Google Scholar
14	Lu L, Li C, Li D, Wang Y, Zhou C, Shao W, Peng J, You Y, Zhang X and Shen X: Cryptotanshinone inhibits human glioma cell proliferation by suppressing STAT3 signaling. Mol Cell Biochem. 381:273–282. 2013. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Nam KS, Oh S, Lee KM, Yoo SA and Shin I: CD44 regulates cell proliferation, migration, and invasion via modulation of c-Src transcription in human breast cancer cells. Cell Signal. 27:1882–1894. 2015. View Article : Google Scholar : PubMed/NCBI
17	Imogen L and Gillham CM: Chemotherapy for lung cancer. N Engl J Med. 346:14982002. View Article : Google Scholar : PubMed/NCBI
18	Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, et al: Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 372:1963–1971. 2014. View Article : Google Scholar
19	Chung PY, Beyens G, Boonen S, Papapoulos S, Geusens P, Karperien M, Vanhoenacker F, Verbruggen L, Fransen E, Van Offel J, et al: The majority of the genetic risk for Paget's disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes. Hum Genet. 128:615–626. 2010. View Article : Google Scholar : PubMed/NCBI
20	Albagha OM, Wani S and Ralston SH: Identification of a functional variant in the TM7SF4 gene that is associated with susceptibility to Paget's disease of bone. Bone. 48:S882011. View Article : Google Scholar
21	Mino-Kenudson M and Mark EJ: Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. Arch Pathol Lab Med. 135:655–664. 2011.PubMed/NCBI
22	Feng N, Luo J and Guo X: Silybin suppresses cell proliferation and induces apoptosis of multiple myeloma cells via the PI3K/Akt/mTOR signaling pathway. Mol Med Rep. 13:3243–3248. 2016. View Article : Google Scholar : PubMed/NCBI
23	Zhang G, Wang C, Sun M, Li J, Wang B, Jin C, Hua P, Song G, Zhang Y, Nguyen LL, et al: Cinobufagin inhibits tumor growth by inducing intrinsic apoptosis through AKT signaling pathway in human nonsmall cell lung cancer cells. Oncotarget. 7:28935–28946. 2016. View Article : Google Scholar : PubMed/NCBI
24	Zhao XZ, Liu Y, Zhou LJ, Wang ZQ, Wu ZH and Yang XY: Role of estrogen in lung cancer based on the estrogen receptor-epithelial mesenchymal transduction signaling pathways. Onco Targets Ther. 8:2849–2863. 2015. View Article : Google Scholar : PubMed/NCBI
25	Zhu Q, Liang X, Dai J and Guan X: Prostaglandin transporter, SLCO2A1, mediates the invasion and apoptosis of lung cancer cells via PI3K/AKT/mTOR pathway. Int J Clin Exp Pathol. 8:9175–9181. 2015.PubMed/NCBI
26	Hu J, Boeri M, Sozzi G, Liu D, Marchianò A, Roz L, Pelosi G, Gatter K, Pastorino U and Pezzella F: Gene signatures stratify computed tomography screening detected lung cancer in high-risk populations. Ebiomedicine. 2:829–840. 2015. View Article : Google Scholar
27	Wan J, Wu W, Chen Y, Kang N and Zhang R: Insufficient radiofrequency ablation promotes the growth of non-small cell lung cancer cells through PI3K/Akt/HIF-1α signals. Acta Biochim Biophys Sin (Shanghai). 48:371–377. 2016. View Article : Google Scholar : PubMed/NCBI